Medical technology company Elucid raises $8 million

Elucid — a medical technology company developing AI software to enable cardiovascular disease detection — announced recently that it raised an $8 million Series A round of funding led by MedTex Ventures and Global Health Impact Fund. And new and existing investors Checkmate Capital, IAG Capital, BlueStone Venture Partners, University of Michigan – Wolverine Venture Fund, Willamette Valley Capital LLC, and Angel Physicians Fund also joined the round.

Elucid is known for using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with known or suspected cardiovascular disease. And advanced clinical insights from ElucidVivo equip physicians with critical information designed to enable precision medicine.

ElucidVivo is known as the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. And the company recently published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts. This unique information informs better treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs.

Jason Bottiglieri also joined Elucid as Chief Commercial Officer. Bottiglieri has more than 25 years of experience in the cardiovascular device space, including as CEO of Infraredx and sales leadership positions at Medtronic, Spectranetics, and Cordis.

Murali Ayyapillai joined as Vice President of Engineering and brings 25 years of imaging R&D experience, most recently as Vice President of iNtuition Development, responsible for TeraRecon’s flagship suite of applications. Before TeraRecon, Ayyapillai was a senior software engineer at Siemens. Pulse 2.0